RxDoctor Payments Data

Daniel Lee, MD

Internal Medicine · West Orange, NJNPI 1811193865

Payments from drug & device makers

$1,484in general payments, 2019–2025

Across 74 payments — averaging $20.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • W. L. Gore & Associates, Inc.$187
  • Boston Scientific$162
  • Merck$144
  • Novo Nordisk$111
  • Novartis$110
  • Exact Sciences$96
  • plus $674 from 21 others

What the payments were for

  • Food & beverage$1,484100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,484 in reported general payments places this provider in the 70th percentile of 4,032 internal medicine providers in New Jersey.

See all internal medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$126,818
Medicare patients
319
Services billed
1,349

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban64$56,503
JanumetSitagliptin Phos/Metformin Hcl36$37,113
JardianceEmpagliflozin17$29,549
JanuviaSitagliptin Phosphate22$28,672
NucyntaTapentadol Hcl13$25,303
MyrbetriqMirabegron19$20,687
OzempicSemaglutide17$16,282
TradjentaLinagliptin22$15,378
XareltoRivaroxaban26$14,602
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr15$11,856
Breo ElliptaFluticasone/Vilanterol20$8,340
InvokanaCanagliflozin12$7,028
Atorvastatin Calcium491$5,867
Humalog Kwikpen U-100Insulin Lispro18$4,932
Diclofenac Sodium15$3,982

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanumet, Januvia$144$65,78558 claims
PfizerEliquis$30$56,50364 claims
Boehringer IngelheimJardiance, Tradjenta$30$44,92739 claims
Johnson & JohnsonXarelto, Invokana$82$21,63138 claims
Astellas Pharma US IncMyrbetriq$23$20,68719 claims
GSKAnoro Ellipta, Breo Ellipta$14$20,19635 claims
Novo NordiskOzempic$111$16,28217 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,032 internal medicine providers in New Jersey.

Other internal medicine in West Orange

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →